These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1322 related items for PubMed ID: 8982148

  • 21. Hydroxyurea therapy in sickle cell anemia patients in Curaçao, The Netherlands Antilles.
    Saleh AW, Velvis HJ, Gu LH, Hillen HF, Huisman TH.
    Acta Haematol; 1997; 98(3):125-9. PubMed ID: 9352741
    [Abstract] [Full Text] [Related]

  • 22. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.
    Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.
    Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ.
    Blood; 1997 Feb 01; 89(3):1078-88. PubMed ID: 9028341
    [Abstract] [Full Text] [Related]

  • 25. The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin.
    el-Hazmi MA, al-Momen A, Warsy AS, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F.
    Acta Haematol; 1995 Feb 01; 93(2-4):57-61. PubMed ID: 7543719
    [Abstract] [Full Text] [Related]

  • 26. Effects of hydroxyurea on blood rheology in sickle cell anemia: A two-years follow-up study.
    Lemonne N, Möckesch B, Charlot K, Garnier Y, Waltz X, Lamarre Y, Antoine-Jonville S, Etienne-Julan M, Hardy-Dessources MD, Romana M, Connes P.
    Clin Hemorheol Microcirc; 2017 Feb 01; 67(2):141-148. PubMed ID: 28759962
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.
    Blood Cells Mol Dis; 2000 Oct 01; 26(5):453-66. PubMed ID: 11112383
    [Abstract] [Full Text] [Related]

  • 29. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India.
    Patel DK, Mashon RS, Patel S, Das BS, Purohit P, Bishwal SC.
    Hemoglobin; 2012 Oct 01; 36(5):409-20. PubMed ID: 22881992
    [Abstract] [Full Text] [Related]

  • 30. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients.
    Al-Nood HA, Al-Khawlani MM, Al-Akwa A.
    Hemoglobin; 2011 Oct 01; 35(1):13-21. PubMed ID: 21250877
    [Abstract] [Full Text] [Related]

  • 31. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia.
    Orringer EP, Blythe DS, Johnson AE, Phillips G, Dover GJ, Parker JC.
    Blood; 1991 Jul 01; 78(1):212-6. PubMed ID: 1712641
    [Abstract] [Full Text] [Related]

  • 32. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW, Kennedy LD.
    Ann Pharmacother; 1997 Nov 01; 31(11):1393-6. PubMed ID: 9391697
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Use of hydroxyurea in children with sickle cell disease: what comes next?
    Ohene-Frempong K, Smith-Whitley K.
    Semin Hematol; 1997 Jul 01; 34(3 Suppl 3):30-41. PubMed ID: 9317199
    [Abstract] [Full Text] [Related]

  • 36. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
    Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K.
    Blood; 2002 Jan 01; 99(1):10-4. PubMed ID: 11756146
    [Abstract] [Full Text] [Related]

  • 37. Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
    Salvia AC, Figueiredo MS, Braga JA, Pereira DF, Brighenti FL, Koga-Ito CY.
    J Oral Pathol Med; 2013 Aug 01; 42(7):570-5. PubMed ID: 23278631
    [Abstract] [Full Text] [Related]

  • 38. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia.
    Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, Visintainer P.
    J Pediatr; 1996 Oct 01; 129(4):559-65. PubMed ID: 8859263
    [Abstract] [Full Text] [Related]

  • 39. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.
    Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, Kuypers F.
    Blood; 1997 Apr 01; 89(7):2554-9. PubMed ID: 9116302
    [Abstract] [Full Text] [Related]

  • 40. Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil.
    Silva-Pinto AC, Angulo IL, Brunetta DM, Neves FI, Bassi SC, Santis GC, Covas DT.
    Sao Paulo Med J; 2013 Apr 01; 131(4):238-43. PubMed ID: 24141294
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 67.